echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Azurity's quasi-Katerzia oral fluid is approved by the U.S. FDA

    Azurity's quasi-Katerzia oral fluid is approved by the U.S. FDA

    • Last Update: 2020-06-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently,
    The u.SFood andDrug(http://Administration (
    FDA(http://has approved Katerzia (amlodiodia, 1mg/mL) oral fluid (1mg/mL) for the treatment of hypertension in children and adults 6 years and older, as well as the treatment of adult coronary artery disease, the(http:// announcedIn June, Cutis Pharma, theof bio
    pharmaceuticalhttp:// announced the acquisition of Silvergate Pharmaceuticals and will merge with it to form its new company, Azurity PharmaceuticalsFounded in Wilmington, Massachusetts, in 1998, CutisPharma is an industry leader in the pharmaceutical complex market, which aims to develop better oral liquid drugs for patients who are unable to take solid tablets and capsulesAzurity Pharmaceuticals' business focus is primarily on meeting the needs of a wide range of patients, especially children and the elderlyThe company's current product (http:// include sepsis (Malay acid Elapli) oral fluid, Qbrelis (Reinopli) oral solution, Xatmep (methotrexate) oral solution, FIRVANQ (vancomycin hydrochloric acid) oral solution, and FIRST composite reagent (http:// box   Katerzia will provide a ready-to-use (simple shake) oral suspension for children aged 6 and over who need or prefer oral aureus, a safe, effective and simple product for administration
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.